Last Price
17.70
Today's Change
+0.03 (0.16%)
Day's Change
17.03 - 18.22
Trading Volume
573,462
Overview
Market Cap
816 Million
Shares Outstanding
46 Million
Avg Volume
1,083,470
Avg Price (50 Days)
15.53
Avg Price (200 Days)
23.59
PE Ratio
13.21
EPS
1.34
Earnings Announcement
27-Feb-2025
Previous Close
17.67
Open
17.58
Day's Range
17.0326 - 18.22
Year Range
11.16 - 35.95
Trading Volume
573,462
Price Change Highlight
1 Day Change
0.17%
5 Day Change
5.42%
1 Month Change
10.69%
3 Month Change
-20.73%
6 Month Change
-33.23%
Ytd Change
-44.69%
1 Year Change
-41.55%
3 Year Change
-69.97%
5 Year Change
-58.47%
10 Year Change
-79.42%
Max Change
152.14%
News and Blogs
No result.
Company Profile
Sector: Healthcare - Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Description:
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Featured Posts
12
Apps
Top Articles
1
CEO Morning Brief
OpenAI in Talks With Regulators to Become For-profit Company — Bloomberg
2
CEO Morning Brief
3
4
5
CEO Morning Brief
Oil Hedging Activity Hits Record in October as Traders Eye Market Risks
#
Stock
Score
Daily Stocks
Stock
Last
Change
Volume
Stock
Last
Change
Volume
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
